A Case of Cefepime-Induced Immune Thrombocytopenia

J Clin Pharm Ther. 2022 Apr;47(4):556-558. doi: 10.1111/jcpt.13546. Epub 2021 Nov 2.

Abstract

What is known and objective: Drug-induced immune thrombocytopenia (DITP) is a rare adverse event. It is often diagnosed using clinical risk criteria, but this can create diagnostic uncertainty.

Case description: A 35-year-old man with disseminated Serratia marcescens infection developed severe thrombocytopenia. A drug-dependent platelet-reactive antibody test demonstrated cefepime-dependent platelet-reactive antibodies which confirmed the diagnosis of DITP.

What is new and conclusion: We describe the first case of cefepime-induced DITP confirmed by a drug-dependent platelet-reactive antibody test. To our knowledge, this is the first proven example of DITP in a fourth-generation cephalosporin.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Blood Platelets
  • Cefepime / adverse effects
  • Humans
  • Male
  • Purpura, Thrombocytopenic, Idiopathic* / chemically induced
  • Purpura, Thrombocytopenic, Idiopathic* / diagnosis
  • Thrombocytopenia* / chemically induced

Substances

  • Cefepime